aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
© aVenture Investment Company, 2024. All rights reserved.
44 Tehama St, San Francisco, CA 94105
Privacy Policy
aVenture Investment Company ("aVenture") is an independent venture capital research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals.
While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision.
aVenture does not offer investment advisory services and is not registered as an investment adviser. The data provided by aVenture does not constitute recommendations or advice, whether by methodology or a statement written by a staff member of aVenture.
Links to external websites do not imply endorsement or affiliation with aVenture. References or links to providers offering the ability to invest in a primary or secondary transaction in a company are for convenience purposes only. They are not solicitations or offers to buy or sell an investment. Remember that past performance does not guarantee future results, and venture capital and private assets should be a contributory part of a diversified portfolio.
Lyra Therapeutics is a clinical-stage biotechnology company focused on developing innovative therapies for the localized treatment of chronic rhinosinusitis (CRS). The company's mission is to provide new solutions for CRS, a debilitating inflammatory disease affecting millions of people worldwide. Lyra's approach aims to deliver treatment directly at the site of impact for CRS patients.
The company's work represents a potential shift in the status quo for CRS treatment. Lyra Therapeutics is dedicated to addressing the long-term symptoms of CRS, including nasal congestion, facial pain and pressure, and nasal discharge, which can persist for months or years. Their innovative approach to localized therapy positions them as a potential leader in advancing CRS treatment options.
Operating Status
Active
Ownership Type(s)
Public
Main Product(s)
Therapeutics, Drugs
Technology
Biotech
Tags
Healthtech
Model Types
Software
Revenue Type(s)
Recurring
Customer Type(s)
Enterprise
Geographic Exposure
Global
When was Lyra Therapeutics founded?
Lyra Therapeutics was founded in 2014.
Where is Lyra Therapeutics’s headquarters located?
Lyra Therapeutics’s headquarters is located in Watertown, MA, US.
When was Lyra Therapeutics’s last funding round?
Lyra Therapeutics’s most recent funding round was for $50M (USD) in May 2023.
How many employees does Lyra Therapeutics have?
Lyra Therapeutics has 66 employees as of Feb 6, 2024.
How much has Lyra Therapeutics raised to-date?
As of July 05, 2023, Lyra Therapeutics has raised a total of $264.1M (USD) since May 26, 2023.
Add Comparison
Total Raised to Date
$264.1M
USD
Last Update May 26, 2023
Last Deal Details
$50M
USD
May 26, 2023
Post Ipo Equity
Total Employees Over Time
66
As of Feb 2024
Lyra Therapeutics Address
480 Arsenal Way
Watertown,
Massachusetts
02472
United States
Source(s): This page includes data and analysis provided by the company, OpenAI, and our research analysts